GSK has entered into an exclusive agreement with Chongqing Zhifei Biological Products to co-promote GSK’s herpes zoster vaccine, Shingrix®, for shingles in China. Through this deal, which is worth up to US$3.059 B, Zhifei will procure specified quantities of Shingrix throughout an initial three-year duration. Only two months prior to the deal, in August 2023, GSK revealed positive results from the Phase IV ZOSTER-076 study, which demonstrated that Shingrix attained 100% efficacy in preventing shingles in adults aged 50 and over in China.